73 related articles for article (PubMed ID: 22735458)
1. The pharmacokinetics of letrozole: association with key body mass metrics.
Jin SJ; Jung JA; Cho SH; Kim UJ; Choe S; Ghim JL; Noh YH; Park HJ; Kim JC; Jung JA; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):557-65. PubMed ID: 22735458
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Tanii H; Shitara Y; Horie T
Eur J Clin Pharmacol; 2011 Oct; 67(10):1017-25. PubMed ID: 21494765
[TBL] [Abstract][Full Text] [Related]
3. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Desta Z; Kreutz Y; Nguyen AT; Li L; Skaar T; Kamdem LK; Henry NL; Hayes DF; Storniolo AM; Stearns V; Hoffmann E; Tyndale RF; Flockhart DA
Clin Pharmacol Ther; 2011 Nov; 90(5):693-700. PubMed ID: 21975350
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence study of two letrozole tablet formulations. Single dose, randomized, open-label, two-way crossover bioequivalence study of letrozole 2.5 mg tablets in healthy volunteers under fasting conditions.
Filipe A; Almeida S; Spínola AC; Trabelsi F; Ortuño J
Arzneimittelforschung; 2008; 58(8):419-22. PubMed ID: 18807583
[TBL] [Abstract][Full Text] [Related]
5. Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients.
Puszkiel A; Dalenc F; Tafzi N; Marquet P; Debled M; Jacot W; Venat-Bouvet L; Ferrer C; Levasseur N; Paulon R; Dauba J; Evrard A; Mauriès V; Filleron T; Chatelut E; Thomas F; White-Koning M
Eur J Pharm Sci; 2024 Aug; 199():106809. PubMed ID: 38788907
[TBL] [Abstract][Full Text] [Related]
6. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Borrie AE; Rose RV; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Dinniwell R; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Tyndale RF; Teft WA; Kim RB
Breast Cancer Res Treat; 2018 Nov; 172(2):371-379. PubMed ID: 30094551
[TBL] [Abstract][Full Text] [Related]
7. Absolute bioavailability of letrozole in healthy postmenopausal women.
Sioufi A; Gauducheau N; Pineau V; Marfil F; Jaouen A; Cardot JM; Godbillon J; Czendlik C; Howald H; Pfister C; Vreeland F
Biopharm Drug Dispos; 1997 Dec; 18(9):779-89. PubMed ID: 9429742
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
Mauras N; Bishop K; Merinbaum D; Emeribe U; Agbo F; Lowe E
J Clin Endocrinol Metab; 2009 Aug; 94(8):2975-8. PubMed ID: 19470631
[TBL] [Abstract][Full Text] [Related]
9. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
[TBL] [Abstract][Full Text] [Related]
10. Effects of a non-steroidal aromatase inhibitor on ovarian function in cattle.
Yapura MJ; Mapletoft RJ; Singh J; Pierson R; Naile J; Giesy JP; Chang H; Higley E; Hecker M; Adams GP
Reprod Fertil Dev; 2012; 24(4):631-40. PubMed ID: 22541551
[TBL] [Abstract][Full Text] [Related]
11. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
13. Letrozole.
Dellapasqua S; Colleoni M
Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):251-9. PubMed ID: 20095792
[TBL] [Abstract][Full Text] [Related]
14. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.
Sioufi A; Sandrenan N; Godbillon J; Trunet P; Czendlik C; Howald H; Pfister C; Ezzet F
Biopharm Drug Dispos; 1997 Aug; 18(6):489-97. PubMed ID: 9267682
[TBL] [Abstract][Full Text] [Related]
15. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.
Noh YH; Ko YJ; Cho SH; Ghim JL; Choe S; Jung JA; Kim UJ; Jin SJ; Park HJ; Song GS; Lim HS; Bae KS
Clin Ther; 2012 Feb; 34(2):305-13. PubMed ID: 22281018
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system.
Miyajima M; Kusuhara H; Takahashi K; Takashima T; Hosoya T; Watanabe Y; Sugiyama Y
J Pharm Sci; 2013 Sep; 102(9):3309-19. PubMed ID: 23712697
[TBL] [Abstract][Full Text] [Related]
18. Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry.
Mareck U; Sigmund G; Opfermann G; Geyer H; Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2005; 19(24):3689-93. PubMed ID: 16299697
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Hertz DL; Douglas JA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Pharmacogenet Genomics; 2021 Jul; 31(5):116-123. PubMed ID: 34096894
[TBL] [Abstract][Full Text] [Related]
20. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
